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ABSTRACT
This study assessed the effects of throat and gut surveillance, combined with enteral vancomycin, on gut
overgrowth, transmission of methicillin-resistant Staphylococcus aureus (MRSA), infections and mortality
in patients admitted to a paediatric intensive care unit (PICU). A 4-year prospective observational study
was undertaken with 1241 children who required ventilation for ‡4 days. Patients identiﬁed as MRSA
carriers following surveillance cultures of throat and rectum received enteral vancomycin. Twenty-nine
(2.4%) children carried MRSA, 19 on admission and nine during treatment in the PICU; one patient was
not able to be evaluated. Overgrowth was present in 22 (75%) of the carriers. Ten (0.8%) children
developed 21 MRSA infections (15 exogenous infections in eight children at a median of 8 days (IQR 3–
10.5); ﬁve primary endogenous infections at a median of 3 days (IQR 1–25) in three children when they
were in overgrowth status; one child developed both types of infection). Enteral vancomycin reduced
gut overgrowth signiﬁcantly, completely preventing secondary endogenous infections. Transmission
occurred on nine occasions over a period of 4 years. Four patients died, two (5.9%) with MRSA
infection, giving a mortality (11.8%) similar to the study population (9.8%). No emergence of
vancomycin-resistant enterococci or S. aureus with intermediate susceptibility to vancomycin was
detected. A policy based on throat and gut surveillance, combined with enteral vancomycin, for
critically-ill children who were MRSA carriers was found to be effective and safe, and challenges the
recommended guidelines of nasal swabbing followed by topical mupirocin.
Keywords Gut overgrowth, infection control, MRSA, paediatric ICU, surveillance, vancomycin
Original Submission: 1 October 2004; Revised Submission: 7 February 2005; Accepted: 15 July 2005
Clin Microbiol Infect 2006; 12: 35–42
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
was ﬁrst identiﬁed in the UK in the 1960s [1], and
was isolated for the ﬁrst time in the USA in an
outbreak in Boston in the late 1960s [2]. Since that
time, the incidence of MRSA infections has contin-
ued to increase [3,4], and spreadofMRSA is nowan
international problem [5]. TheMRSA infection rate
in childrenwas believed originally to be lower than
in adults. However, recent studies have reported
an increasing incidence of bloodstream infections
caused by MRSA acquired in the paediatric care
setting [6,7]. Neonatal units are another area of
concern, with several reported outbreaks of severe
MRSA pneumonia and septicaemia [8,9].
Nasal carriage of MRSA has been considered to
be the source of invasive MRSA infections, and is
thought to be crucial in the spread of MRSA [10].
Topical mupirocin has been recommended
widely for the clearance of nasal MRSA [11].
Infection control programmes that include nasal
screening, combined with intra-nasal mupirocin,
skin decontamination with an antimicrobial soap,
and placement of patients under contact isolation
precautions, were only effective temporarily in
the control of MRSA transmission [12,13]. Indeed,
two randomised trials that evaluated nasal mup-
irocin for clearing MRSA showed poor efﬁcacy in
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eradicating extra-nasal body sites, including the
gut [14,15].
Oropharyngeal and gastrointestinal carriage of
MRSA in children and adults is an important
source of MRSA infection [16,17]. Nasopharyngeal
and gut ﬂora determine skin carriage on the upper
part of the body, such as the hands, arms and
axillae, and the lower part of the body, including
the perineum and inguinal areas, respectively [17].
Touching intact areas of the skin during patient
care can result in contamination of healthcare
workers’ hands with MRSA present on the
patient’s skin, and may lead to the transmission
of MRSA via the carers’ hands to other patients. A
policy based on surveillance cultures of throat and
rectum, combined with enteral vancomycin, has
been used effectively to controlMRSAoutbreaks in
ventilated adult patients [18–21]. The present
study investigated the efﬁcacy of this policy in
controlling MRSA in critically-ill children.
PATIENTS AND METHODS
Setting
The study was conducted in a 20-bed regional paediatric
intensive care unit (PICU), with an admission rate of >1000
patients ⁄ year. Of total admissions, 40% are for post-operative
cardiac care, 40% are for medical conditions, and the remain-
der are for surgical conditions, including burns. Overall
mortality in the unit is 4.5%, with a predicted mortality rate
of 6.25% calculated with the paediatric index of mortality
(PIM) [22], and a standardised mortality rate of 0.72.
Design and endpoints
The primary aim of this prospective observational single-
centre study was to determine the efﬁcacy of a strategy using
surveillance cultures of throat and rectum, combined with
enteral vancomycin, in the eradication of MRSA carriage and
the prevention of secondary endogenous MRSA infections. A
secondary endpoint was to monitor the emergence of vanco-
mycin-resistant enterococci (VRE) and S. aureus with interme-
diate susceptibility to vancomycin (VISA) [23].
Patients
The study was conducted during a 48-month period between
1 March 1999 and 28 February 2003. The subjects were children
admitted to the PICU who required mechanical ventilation for
a minimum of 4 days. The institutional ethics review board
approved the study.
Antibiotic policy
The criteria used for the choice of an antimicrobial agent for
either prophylaxis or treatment, were: (i) protection of the
indigenous ﬂora, which is required to control the overgrowth of
MRSA. Cephradine was used as the ﬁrst-line anti-staphylococ-
cal agent, as ﬂucloxacillin disrupts gut ecology to a greater
extent than does cephradine [24]; (ii) the use of antimicrobial
agents with the lowest potential for the development of
resistance, deﬁned as agents towhich no resistancehas emerged
within 2 years of general use. Antimicrobial agents with a high
potential for the development of resistance, such as linezolid,
were only prescribed on a restricted basis [25]; (iii) the use of
agentswith anti-inﬂammatoryproperties, e.g., aminoglycosides
and glycopeptides, or treatment with b-lactams and ﬂuoroqu-
inolones, which may increase cytokine production [26].
Antibiotic use fell into three categories: (i) surgical prophy-
laxis; (ii) selective decontamination of the digestive tract, i.e.,
patients with the abnormal carrier state, colonisation or
infection (e.g., with aerobic Gram-negative bacilli (AGNB)
and ⁄or MRSA) received enteral polymyxin E ⁄ tobramycin [27]
and ⁄or vancomycin [28] (Table 1); and (iii) therapeutic intra-
venous regimens.
Device policy
Staphylococci, both coagulase-positive and -negative, have an
afﬁnity for plastic devices. Most patients who require
long-term intensive care have indwelling devices, including
intubation tubes, intravascular lines and urinary catheters,
tracheostomy and ⁄ or gastrostomy tubes. The chance that these
devices become contaminated with MRSA is substantial in a
patient who is a carrier of MRSA in the nose, throat, gut or skin
[29]. A strict device policy was in place in the PICU. Devices
were changed immediately for any case in which diagnostic
samples were positive for MRSA; e.g., in the case of positive
tracheal aspirates, the ventilation tube was replaced; in the
case of a positive blood culture taken through an indwelling
vascular line or a positive vascular catheter site swab, the
intravascular lines were removed and replaced.
Sampling policy
Surveillance samples of throat and rectum were taken on
admission to detect the importation of MRSA, and thereafter
twice-weekly (Monday and Thursday) to identify acquisition
of MRSA in the PICU. Surveillance samples were distin-
guished from diagnostic samples, which were taken solely on
clinical indication from normally sterile sites, including lower
airways, blood and wounds.
Table 1. Enteral and topical vancomycin treatment regi-
mens [28]
Carriage site Enteral treatment for 5 days
Nasal 2% cream 4 times-daily
Oropharyngeal 2% paste (0.5 g) or 4 times-daily
2% gel (0.5 g) or 4 times-daily
5 mg lozenge 4 times-daily
Gut 40 mg ⁄ kg ⁄day oral suspension 4 times-daily
Skin 4% chlorhexidine bath ⁄ shower Alternating days
Colonisation ⁄ infection site
Topical treatment for 3 days and enteral
treatment for 5 days (as above)
Lower airways Nebulised 5 mg ⁄ kg ⁄day 4 times daily
Wounds 2% aquaform or
2% tauroline dressing
Twice daily
Gastro ⁄ tracheostoma 2% paste Twice daily
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Microbiology
Surveillance samples
Surveillance cultures of throat and rectal swabs were pro-
cessed qualitatively and semiquantitatively to detect the level
of MRSA carriage [30]. Each swab was streaked on to
Staphylococcus medium no. 10 (Oxoid, Basingstoke, UK) using
the four-quadrant method, and then the tip was broken off into
5 mL brain-heart infusion enrichment broth (BHI; Oxoid). All
cultures were incubated at 37C. The agar plate was examined
after incubation for 1 and 2 nights. Additionally, if the
enrichment broth was turbid after overnight incubation, it
was then inoculated on to a Staphylococcus agar plate. A
semiquantitative estimation was made by grading growth
density on a scale of 1+ to 5+ [31].
Diagnostic samples
Lower airway secretions, urine and pus were processed in a
qualitative and semiquantitative way with standard microbio-
logical methods. Blood cultures were processed using the
BACTEC 9240 system (Becton Dickinson, Oxford, UK). S. au-
reus isolates were tested for methicillin susceptibility by a strip
diffusion method (Mast, Bootle, UK) on Mueller-Hinton agar
(Oxoid) containing NaCl 2% w ⁄v. Test cultures were inocu-
lated in streaks across the plate, and a strip containing 25 lg
methicillin was applied across the streaks. Plates were incu-
bated at 30C for 24 h. S. aureus isolates growing up to the strip
were tentatively classiﬁed as methicillin-resistant. Resistance
was conﬁrmed by a methicillin MIC of ‡8 mg ⁄L with Etests
(AB Biodisk, Solna, Sweden) [32], and with the Mastalex-
MRSA latex agglutination test for PBP2a (Mast). MICs of
vancomycin were determined with Etests; S. aureus isolates
with MICs of 8–16 mg ⁄L were deﬁned as intermediately-
susceptible [33]. Faecal samples and rectal swabs from all
patients were screened for enterococci as described by Endtz
et al. [34]. Vancomycin MICs were determined by Etests, with
enterococci with MICs ‡16 mg ⁄L deﬁned as resistant [35].
Infection control policy
When MRSA was isolated from any site, the patient was
moved to an isolation cubicle and cared for as an infected case.
Swabs were taken from anterior nares, throat and rectum to
determine the extent of carriage. If more than one case
occurred, all patients who had been in the same ward during
the 3-day period before the index case was identiﬁed had
swabs taken from anterior nares and throat ⁄ rectum. Nursing
staff who attended the index case had swabs taken of anterior
nares, throat, and rectum, and the occupational health depart-
ment was informed. If the index case had undergone surgery,
children on the same surgical list were screened. If all
screening results were negative, no further action was taken.
If any patients were positive, they were managed in the same
way as the index case. If any staff were positive, they were
treated as an index case and excluded from work until all
screening swabs were negative.
Terminal cleaning of cubicles
All equipment used was cleaned in the cubicle and removed
before the cleaning schedule. All horizontal surfaces were
cleaned with a solution of detergent and water, followed by
disinfection with a solution of a chlorine-releasing agent at a
concentration of 10 000 ppm available chlorine (Haz-tab Gran-
ules H8800; Guest Medical, Edenbridge, UK) and then dried
thoroughly. Any curtains were sent to the laundry. Vertical
blinds were cleaned in the same way as surfaces and by
vacuum attachment.
Deﬁnitions
A patient was deﬁned as a carrier if MRSA was isolated from
at least two consecutive surveillance samples of throat and ⁄ or
rectum, in any concentration, for a period of at least 1 week
[36]. Overgrowth was deﬁned as the isolation of MRSA in a
concentration graded at least 3+, or ‡105 CFU ⁄mL of saliva
or ⁄g of faeces [19]. Infection was deﬁned as a microbiologically
proven clinical diagnosis of inﬂammation (local and ⁄ or gen-
eralised). This included not only clinical signs, but also the
presence of a moderate (+ +) number of leukocytes and MRSA
(‡3+ or ‡105 CFU ⁄mL) in diagnostic samples obtained from an
internal organ, or the isolation of MRSA from a blood culture
[36]. All infections were diagnosed according to CDC criteria
[37]. Primary endogenous infection was deﬁned as infection
caused by MRSA that was already carried upon admission to
the PICU [20]. This type of infection occurs generally within
1 week of admission to PICU. Secondary endogenous infection
was deﬁned as infection caused by MRSA acquired after
admission to the ICU, i.e., the initial throat and gut swabs were
negative for MRSA, but became positive subsequently. The
mechanism of spread of potentially pathogenic microorgan-
isms (PPM), including MRSA, is usually transmission via the
hands of carers, with acquisition in the oropharynx, followed
by carriage and overgrowth in the digestive tract. Subse-
quently, colonisation and infection of the internal organs can
occur [20]. Secondary endogenous infections generally develop
after 1 week. Exogenous infection was deﬁned as infection
caused by MRSA introduced into the patient from the
environment, both animate and inanimate sources. MRSA
was transferred directly, omitting the ﬁrst stage of carriage, to
a site where colonisation or infection then occurred, e.g., burn
wounds, tracheostomy or gastrostomy. This type of infection
can occur at any time during treatment in a PICU [20]. The
carriage index was the sum of all semiquantitative MRSA
growth densities isolated from surveillance swabs, divided by
the total number of swabs taken [18,20].
Analytical methods
Data were collected prospectively and entered into an Access
97 database (Microsoft, Redmond, USA). Prediction of mor-
tality, using the PIM, was calculated on the patient’s ﬁrst
contact with the PICU team [22]. Data included age (months),
gender, PIM, underlying diagnosis, length of stay (days),
presence or absence of infection, causative microorganism,
type of infection, day of infection onset, antimicrobial suscep-
tibility pattern and outcome. Results were expressed as a
fraction of the total study population; median and interquartile
ranges (IQRs), or mean and standard deviation (SD) or 95% CI
were used to describe the demographic distributions.
Parametric data were analysed using the Student t-test.
Non-parametric data were analysed using the Wilcoxon-
Mann–Whitney or Fisher’s exact tests. Correlation was
analysed using Pearson’s correlation coefﬁcient. Statistical
calculations were performed with SPSS v.11.0.0 (SPSS Inc.,
Chicago, IL, USA), with p < 0.05 considered to be statistically
signiﬁcant.
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RESULTS
Demographics
In total, 1241 patients were included in the
study. There were 34 patients positive for
MRSA, with a total of 49 admissions during
the study period. The male : female ratio was
23 : 11. Median age of the MRSA-positive chil-
dren was 5.4 months (IQR 2.5–17.7), which was
similar to the entire study population (median
3.6 months; IQR 0.5–18.4; p 0.16). Ten children
with congenital heart disease were positive for
MRSA. Fourteen MRSA patients were medical:
ﬁve with a respiratory tract infection, two with
a chronic neurological condition plus respiratory
failure, two with sepsis, two with tracheomala-
cia, one with laryngeal haemangioma plus
respiratory tract infection, one with neurode-
generative disease plus respiratory tract infec-
tion, and one with multiple congenital
anomalies. Ten MRSA patients were surgical:
six children with burns, and four post-surgery.
All the children had indwelling devices during
their PICU stay: 34 with an endotracheal tube,
29 with a central venous line, 34 with an arterial
line, 30 with a urinary catheter, three with a
tracheostomy, three with a gastrostomy. The
median length of stay was 11 days (IQR 8–21).
The 34 MRSA-positive patients were hospital-
ised for a total of 1030 days. The mean PIM
score of this MRSA group was 0.096 (SD 0.105),
which was similar to the entire study popula-
tion (mean PIM 0.108; SD 0.131; p 0.56).
Carriers
There were 29 (2.4%) MRSA carriers among the
1241 patients in the study population. Nineteen
children imported MRSA into the unit, nine
children acquired MRSA while being treated in
the PICU, and one patient was not able to be
evaluated. MRSA carriage developed after a
median time of 5 days (IQR 4–13). Fifteen
patients carried MRSA in the throat only, three
solely in rectum, and 11 in throat and rectum.
In total, 14 patients received enteral vancomy-
cin, as they were still ventilated in the PICU
after detection of the carrier state. MRSA was
eradicated in 11 (79%) of these children after a
median of 6 days (IQR 3.5–9.75). In two of the
remaining three patients, the MRSA carrier load
decreased from 5+ to 3+.
Overgrowth
Twenty-two of 29 carriers showed overgrowth
(Table 2). The three children who developed ﬁve
primary endogenous infections belonged to this
group. The ﬁve primary endogenous infections
occurred at a median of 3 days (IQR 1–25) when
the level of MRSA was at least 3+, i.e., when the
patient was in an overgrowth state. All these
children received enteral vancomycin for the
eradication of MRSA overgrowth.
Carriage index
The carriage index of the MRSA carrier popula-
tion was approximately 3+ upon admission, i.e.,
overgrowth (Fig. 1). The administration of enteral
vancomycin reduced the carriage index to <1+
after 2 weeks. There was a steady decline in the
carriage index with the commencement of the
5-day course of enteral vancomycin (Fig. 1). The
Pearson’s coefﬁcient of correlation (r) was )0.84
(p 0.004).
Table 2. The distribution of MRSA load and its relation-
ship to endogenous infection in critically-ill children




























Pearson’s correlation coefficient:  r =–0.844, p 0.004. 
Fig. 1. The impact of enteral vancomycin on the level of
MRSA carriage using the carriage index
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Infections
During a 4-year period, there were ten (0.8%)
patients with 21 MRSA infections; four children
with burns, and one each with exomphalos
repair plus tracheomalacia, multiple congenital
anomalies, chronic lung disease plus bronchio-
litis, neurodegenerative disease plus bronchioli-
tis, pneumonia and laryngeal haemangioma
with a tracheostomy. MRSA infection developed
after a median period of 8 days (IQR 3–10.5);
most were wound infections (14), followed by
bloodstream infections (4), and lower airway
infections (3). Fifteen (71%) infections were of
exogenous pathogenesis and occurred at a
median of 8 days (IQR 3–10.5): 11 separate
episodes of infection in four burn patients, and
one each of septicaemia, exomphalos repair plus
tracheomalacia, multiple congenital anomalies,
and pneumonia. Five (24%) infections were
caused by MRSA present in the ﬂora upon
admission of three children (i.e., primary endog-
enous infection) and occurred at a median of
3 days (IQR 1–25): two septicaemias, one endo-
carditis, one chest infection and one central
venous line infection in a burn patient. The
pathogenesis for the remaining infection (laryn-
geal haemangioma with a tracheostomy) could
not be assessed because of an absence of
admission surveillance samples. There were no
secondary endogenous infections, implying that
eradication of MRSA carriers was successful in
preventing new infections following transmis-
sion via the hands of carers.
Diagnostic and surveillance samples
During the 4-year period, the 34 patients account-
ed for a total of 1611 samples, 522 surveillance
and 1089 diagnostic. Neither VRE nor VISA was
isolated from any of these samples.
Mortality
Four patients died, giving a mortality rate of
11.8%; one child had cerebral palsy, and the
other three had severe burns. Two patients were
free from MRSA at the time of death. Pneu-
monia and endocarditis caused by MRSA were
reasons for death in two of the severely burnt
children (5.9% of the 34 MRSA-positive chil-
dren).
DISCUSSION
Five messages emerge from this observational
study of 34 children who required ventilation for
a minimum period of 4 days: (i) 70% of the
patients who carried MRSA carried it in their
admission ﬂora; (ii) 79% of the MRSA carriers
who received enteral vancomycin cleared MRSA;
(iii) MRSA overgrowth was controlled by enteral
vancomycin, with subsequent absence of secon-
dary endogenous infections, even though the
policy of treating conﬁrmed carriers did not
completely prevent transmission; (iv) MRSA
infections in the unit were an exogenous problem;
(v) there was no emergence of vancomycin resist-
ance, as neither VRE nor VISA were isolated from
the 1611 samples.
MRSA was largely a problem of importation
into the unit, as 19 of 29 children carried MRSA in
their ﬂora upon admission. Surveillance cultures
are indispensable for detection of the asympto-
matic carrier state, and recent data have demon-
strated that a surveillance set should include
throat and gut samples, as the digestive tract
cannot be ignored [16,17]. Detection of MRSA
carriers, both upon admission and later during
treatment, is crucial to allow prompt isolation and
treatment. Without surveillance, diagnostic sam-
ples, including tracheal aspirate, blood, urine and
pus, are the only way to detect MRSA in the unit.
This traditional approach of taking diagnostic
samples results in an inherent and substantial
delay which promotes dissemination of MRSA
throughout the unit, with consequent endemicity.
The second component of the MRSA control
policy was the administration of enteral vanco-
mycin following positive throat and gut cultures.
This approach challenges the traditional recom-
mendations of nasal surveillance and topical
mupirocin [14,15]. Enteral vancomycin aims to
eradicate carriage, or lower the carriage load of
MRSA, with two clinical and epidemiological
aims [38]: (i) the control of endogenous MRSA
infection in an individual patient; and (ii) the
control of MRSA dissemination to protect other
children in the unit from acquiring MRSA fol-
lowing transmission via hands of carers.
Overgrowth of potential pathogens including
MRSA is a risk-factor for endogenous infection
[19,39,40]. MRSA overgrowth was an ‘early’
problem in the unit studied (Fig. 1), in line with
the ﬁve primary endogenous infections that
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occurred at a median of 3 days (Table 2). Once
overgrowth was under control, there were no
secondary endogenous infections in this study.
The use of enteral vancomycin was successful, in
that the oropharyngeal gel containing vancomy-
cin (2% w ⁄v) and the vancomycin solution
(40 mg ⁄kg ⁄day) administered via a nasogastric
tube [28] eradicated or reduced the level of
carriage, as demonstrated by the steady decline
in the carriage index (Fig. 1). Critically-ill patients
are unable to clear abnormal gut ﬂora, including
MRSA, because of their underlying disease [41].
Therefore, this decline in MRSA overgrowth
reﬂects an effect of enteral vancomycin treatment,
rather than a general improvement in the pa-
tients’ health status. Additionally, it is common
experience that the traditional use of only paren-
teral vancomycin fails to clear MRSA from nose,
throat, gut and wounds [19,38,42].
Epidemiologically, gut overgrowth promotes
the spread of MRSA via hands of carers [18,19,43].
Long-stay patients invariably have overgrowth in
their throat and gut, and washing a patient or
changing a diaper may lead to contamination of
the hands of carers. Eradicating and reducing
overgrowth results in a reduction in the overall
levels of MRSA density on the skin of patients,
and thus a reduced risk of contaminating the
hands of carers. In this way, hand-washing
becomes more effective in a unit that uses enteral
vancomycin. The policy was largely successful, as
only nine patients in 4 years acquired MRSA
while in the PICU. Enteral vancomycin was
administered to conﬁrmed MRSA carriers during
the study. The unavoidable delay until surveil-
lance culture results are available means that, for
a short period of time, as yet unidentiﬁed MRSA
carriers are still a potential source of transmission.
This factor may have played a role in these nine
cases. An alternative preventative approach
would be to commence enteral vancomycin treat-
ment immediately for all admitted patients while
awaiting the results of admission surveillance
samples [19]. Prophylactic vancomycin is recom-
mended only in ICUs with a serious MRSA
problem, i.e., one or more infections per week
[38]. In the unit described in the present study,
where MRSA infection occurs on average only
once in 2 months, it is appropriate to use vanco-
mycin only as treatment for carriage.
The proﬁle ⁄ risk-factors of the children with
MRSA carriage or infection in the unit included
burn patients, chronic illness (particularly neuro-
logically impaired children and those with
multiple co-morbidities), indwelling devices
(including tracheostomies, gastrostomies) and
central venous lines. Age and antibiotic regimens
did not inﬂuence MRSA acquisition in this group.
The mortality in this group of children was higher
than the background mortality within the PICU,
even though the risk of mortality upon admission
was similar to the background risk (p 0.56). The
number of deaths was too small to project
conﬁdently a causal effect.
A particular group of children in this hospital
at high risk for exogenous infections are those
with burns. Despite repeated investigation and
cleansing of the burns unit, MRSA recurred on
several occasions following MRSA-free periods. It
is suspected that there is transmission from
MRSA-positive burn patients seen in the outpa-
tient clinics. MRSA infection in the PICU is
mainly an exogenous problem, since the burn
patients were MRSA-free upon admission to the
PICU and their wounds subsequently became
positive for MRSA without previous carriage in
throat and gut. Interestingly, most of these
patients acquired MRSA while there were no
other MRSA-positive patients present in the
PICU. This suggests that an external or visiting
source may be responsible. High standards of
hygiene are crucial to prevent this type of infec-
tion. Wounds colonised or infected with MRSA
were treated in the PICU with aquaform vanco-
mycin 2% w ⁄ v dressing to eradicate exogenous
colonisation or infection [19].
Extensive efforts were made during this 4-year
study to evaluate 1611 samples for the possibility
of colonisation or infection with VRE and VISA in
diagnostic samples, and of overgrowth of VRE
and VISA in surveillance samples. The failure to
detect VRE or VISA, a described concern of an
enteral vancomycin protocol [44], may be associ-
ated with: (i) the restricted use of enteral vanco-
mycin [45]; (ii) the use of parenteral antimicrobial
agents that spare the indigenous ﬂora [24,46]; and
(iii) the use of the protocol in an intensive care
and hospital setting with no previous isolation of
VRE and VISA. Of the 1241 children included in
this study, only 14 (1%) received enteral vanco-
mycin, which is hardly indicative of liberal use of
vancomycin. Recent published evidence shows
that parenteral antimicrobial agents that disturb
the patient’s gut ecology, rather than high doses
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of enteral vancomycin, promote the emergence of
VRE [27,45,46]. In addition, VRE and VISA are
usually imported into an ICU, hence it is not
feasible to speculate on the possibility of increas-
ing rates of VRE and VISA. However, the present
study is in line with four recent European studies
using selective decontamination of the digestive
tract, including enteral vancomycin [18–21], none
of which reported an increased infection rate with
VRE or VISA. These European studies were
conducted in ICUs with no history of VRE,
although one study detected importation of
VRE, but rapid and extensive spread did not
occur [19].
In conclusion, surveillance cultures of throat
and rectum detected MRSA importation into and
transmission within a unit. Enteral vancomycin
eradicated the abnormal carrier state of MRSA,
and kept PICU patients infection-free without the
emergence of VRE and VISA. This novel approach
challenges the conventional strategy of nasal
surveillance combined with the use of intranasal
mupirocin.
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